Monitoring changes in quality of life in patients with lung cancer under treatment with chemotherapy and co administration of zoledronic acid by using specialized questionnaires

Due to the severity of the primary disease in patients with lung cancer, quality of life (QoL) is often overlooked. Factors that form QoL should be taken in consideration when planning the appropriate treatment and determining therapy targets, because of the increasing frequency of bone metastasis l...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of Cancer Vol. 9; no. 10; pp. 1731 - 1736
Main Authors:	Tremmas, Ioannis, Petsatodis, George, Potoupnis, Michael, Laskou, Stella, Giannakidis, Dimitrios, Mantalovas, Stylianos, Koulouris, Charilaos, Katsaounis, Athanasios, Pavlidis, Efstathios, Amaniti, Aikaterini, Huang, Haidong, Bai, Chong, Shi, Dongchen, Dardas, Athanasios, Zarogoulidis, Paul, Sardeli, Chrisanthi, Konstantinou, Fotis, Katsikogiannis, Nikolaos, Zarogoulidis, Konstantinos, Karapantzos, Ilias, Karapantzou, Chrysanthi, Shen, Xiaping, Kesisoglou, Isaak, Sapalidis, Konstantinos
Format:	Journal Article
Language:	English
Published:	Australia Ivyspring International Publisher 01-01-2018
Subjects:	Research Paper lung cancer bone metastasis zoledronic acid sleep quality
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Due to the severity of the primary disease in patients with lung cancer, quality of life (QoL) is often overlooked. Factors that form QoL should be taken in consideration when planning the appropriate treatment and determining therapy targets, because of the increasing frequency of bone metastasis leading to high levels of pain. Purpose of this study is to assess quality of life in patients with lung cancer, before and after treatment combined with zoledronic acid. QoL was assessed in 80 patients (49 males-31 females), of which 45 developed bone metastasis. Prior and post treatment (with co administration of zoledronic acid) seven reliable scales: Pittsburgh Sleep Quality index (PSQI), Epworth Sleeping Scale (ess), Dyspnea Scale (ds), Fatigue Severity Scale (FSS), Brief Pain Inventory (BPI), Fact-G scale for sleep quality and EQ-5D for general health condition. Statistically positive correlations were verified between PSQI-DS, PSQI-FSS, BPI-ESS, DS-FSS, DS-BPI and BPI-FSS (p<0,005) prior and post treatment. Patients sleep quality was improved, pain levels decreased and betterment in quality of life was marked (p<0,001). Although significant decrease in fatigue levels was observed (p<0,001) there has been an increase in dyspnea symptoms (p<0,001). Significant improvement was apparent when zoledronic acid was co administered in any treatment in patients with lung cancer. Sleep quality, fatigue and pain parameters also improved, with no positive impact on the symptoms of dyspnea.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 These authors contributed equally to this work. Competing Interests: The authors have declared that no competing interest exists.
ISSN:	1837-9664 1837-9664
DOI:	10.7150/jca.24785